People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

We have made great strides in the medical community, with people having access to life-saving physical drugs as well as mental health medicine. A recent approval made by the FDA could be a great step ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...